Are there clinically relevant prognostic factors in diffuse large B-cell lymphoma beyond International Prognostic Index?

ABSTRACT:

Background

Diffuse large B-cell lymphoma (DLBCL) has variable prognosis, with only 50 to 60% of patients cured by standard first line treatment. Identifying patients unlikely to benefit from standard first line therapy is therefore crucial. Schmitz's study identified four molecular subtypes of DLBCL with differing prognoses: MCD, BN2, N1, and EZB, with BN2 and EZB showing more favorable outcomes. This study aimed to evaluate the effectiveness of the Archer FusionPlex Lymphoma Assay in identifying the newly defined genetic subtypes of DLBCL, while also exploring the association between immunohistochemical (IHC) and next-generation sequencing (NGS) methods for classifying the cell of origin (COO) and assessing their predictive value for patient survival.

Materials and methods

SUBMITTER: Miljkovic M 

PROVIDER: S-EPMC12707449 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature